Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:CYTK NASDAQ:FREQ NASDAQ:GOSS NASDAQ:IMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.74-1.8%$1.74$1.41▼$5.01$9.57M1.1926,725 shs18,177 shsCYTKCytokinetics$36.81+0.6%$32.73$29.31▼$61.38$4.39B0.591.53 million shs302,258 shsFREQFrequency Therapeutics$0.30$0.58$0.18▼$16.00$10.94M0.84822,537 shs309,164 shsGOSSGossamer Bio$1.39+1.8%$1.22$0.66▼$1.55$314.81M1.861.44 million shs349,440 shsIMABI-Mab$2.15+4.6%$1.75$0.60▼$3.08$175.16M1.4394,375 shs181,246 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-5.85%+1.14%-4.84%+14.19%-55.19%CYTKCytokinetics-0.11%+7.94%+5.94%-5.33%-33.39%FREQFrequency Therapeutics0.00%0.00%0.00%0.00%0.00%GOSSGossamer Bio0.00%+11.02%+8.80%+64.85%+16.24%IMABI-Mab-11.26%-8.07%-22.35%+207.81%+35.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics2.5658 of 5 stars3.54.00.00.00.00.81.3CYTKCytokinetics4.1995 of 5 stars4.52.00.04.61.50.80.0FREQFrequency TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGOSSGossamer Bio3.688 of 5 stars3.51.00.04.71.51.70.0IMABI-Mab3.0162 of 5 stars3.73.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50791.83% UpsideCYTKCytokinetics 2.93Moderate Buy$70.9292.66% UpsideFREQFrequency Therapeutics 0.00N/AN/AN/AGOSSGossamer Bio 3.00Buy$7.33429.48% UpsideIMABI-Mab 3.33Buy$6.00179.72% UpsideCurrent Analyst Ratings BreakdownLatest CYTK, FREQ, IMAB, GOSS, and APRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.007/9/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.006/27/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.006/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.006/9/2025CYTKCytokineticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.005/29/2025CYTKCytokineticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.005/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.005/14/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.005/13/2025CYTKCytokineticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.41N/AN/A$3.55 per share0.49CYTKCytokinetics$18.47M238.03N/AN/A($1.15) per share-32.01FREQFrequency Therapeutics$14.07M0.78N/AN/A$1.96 per share0.15GOSSGossamer Bio$114.70M2.74N/AN/A$0.13 per share10.65IMABI-Mab$3.89M45.03N/AN/A$2.47 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)CYTKCytokinetics-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)FREQFrequency Therapeutics-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/AGOSSGossamer Bio-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)Latest CYTK, FREQ, IMAB, GOSS, and APRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AFREQFrequency TherapeuticsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.905.90CYTKCytokineticsN/A5.995.99FREQFrequency TherapeuticsN/A5.815.81GOSSGossamer Bio6.705.715.71IMABI-MabN/A22.3522.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%CYTKCytokineticsN/AFREQFrequency Therapeutics13.18%GOSSGossamer Bio81.23%IMABI-Mab38.38%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%CYTKCytokinetics2.70%FREQFrequency Therapeutics16.80%GOSSGossamer Bio6.70%IMABI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataCYTKCytokinetics250119.43 million116.20 millionOptionableFREQFrequency Therapeutics4636.52 million30.39 millionNot OptionableGOSSGossamer Bio180227.30 million212.07 millionOptionableIMABI-Mab38081.66 million63.61 millionOptionableCYTK, FREQ, IMAB, GOSS, and APRE HeadlinesRecent News About These CompaniesI-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025July 9 at 8:05 PM | msn.comI-Mab (NASDAQ:IMAB) Given Buy Rating at HC WainwrightJuly 9 at 9:03 AM | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for I-Mab (NASDAQ:IMAB)July 9 at 9:03 AM | marketbeat.comI-Mab Reports Encouraging Phase 1b Data for Givastomig in Combination with Nivolumab and mFOLFOX6 at ESMO GI 2025, Confirming 83% Objective Response Rate in Gastric ... - NasdaqJuly 4, 2025 | nasdaq.comI-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025July 2, 2025 | globenewswire.comI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - MorningstarJuly 2, 2025 | morningstar.comMI-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer ResearchJune 30, 2025 | globenewswire.comI-Mab (NASDAQ:IMAB) Price Target Raised to $5.00June 27, 2025 | marketbeat.comI-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025June 26, 2025 | globenewswire.comI-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025June 18, 2025 | manilatimes.netMI-Mab Biopharma: I-Mab Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 13, 2025 | finanznachrichten.deI-Mab regains compliance with Nasdaq’s listing ruleJune 12, 2025 | kalkinemedia.comKI-Mab Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 12, 2025 | manilatimes.netMI-Mab Regains Nasdaq Compliance with Minimum Bid PriceJune 12, 2025 | tipranks.comI-Mab regains Nasdaq compliance as shares maintain $1 minimum bidJune 12, 2025 | investing.comI-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden CrossJune 11, 2025 | zacks.comI-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?June 6, 2025 | zacks.comI-Mab to Participate in the H.C. Wainwright “HCW@Home” SeriesJune 3, 2025 | finance.yahoo.comI-Mab Advances Givastomig in Gastric Cancer with Promising Clinical DataJune 2, 2025 | tipranks.comI-Mab stock surges on Lucid Capital’s buy rating initiationMay 29, 2025 | za.investing.comI-Mab stock surges on Lucid Capital's buy rating initiationMay 28, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTK, FREQ, IMAB, GOSS, and APRE Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.74 -0.03 (-1.81%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Cytokinetics NASDAQ:CYTK$36.81 +0.22 (+0.61%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Frequency Therapeutics NASDAQ:FREQFrequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Gossamer Bio NASDAQ:GOSS$1.38 +0.03 (+1.84%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.I-Mab NASDAQ:IMAB$2.14 +0.10 (+4.63%) As of 01:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
